Literature DB >> 10942036

Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness.

G G Nomikos1, B Schilström, B E Hildebrand, G Panagis, J Grenhoff, T H Svensson.   

Abstract

It has previously been shown that the reinforcing and dependence-producing properties of nicotine depend to a great extent on activation of nicotinic receptors within the ventral tegmental area (VTA), i.e. the site of origin of the mesolimbocortical dopaminergic projection. Based on the data reviewed in the present study, it is suggested that nicotine by stimulating presynaptic alpha7 nicotinic receptors within the VTA, that are probably localized on glutamatergic afferents from the medial prefrontal cortex, produces sequentially an increase in glutamate concentrations, stimulation of NMDA receptors found on dopamine (DA)-containing neurons in the VTA, enhanced firing activity of VTA-DA neurons, augmented DA release in the nerve terminal regions, and enhanced c-fos expression in the dopaminergic projection areas through activation of D1-DA receptors. In addition, it appears that alpha7 nicotinic receptors within the VTA are directly involved in nicotine-related reward and withdrawal responses. These data may be instrumental in understanding how nicotine interacts with the mesolimbocortical dopaminergic system, which is perhaps the most important component of the neural mechanisms underlying nicotine dependence. These results may also contribute to unraveling the cellular basis of nicotine's association with neuropsychiatric disorders, thereby offering the prospect of new therapeutic advances for their treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942036     DOI: 10.1016/s0166-4328(00)00204-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  39 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

3.  Genetic dissociation of two behaviors associated with nicotine addiction: beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome.

Authors:  M Besson; V David; S Suarez; A Cormier; P Cazala; J-P Changeux; S Granon
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

4.  Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.

Authors:  Thomas J Gould; Michael C Lewis
Journal:  Learn Mem       Date:  2005 Jul-Aug       Impact factor: 2.460

Review 5.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 7.  Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine.

Authors:  Justin W Kenney; Thomas J Gould
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 8.  Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits.

Authors:  Huibert D Mansvelder; Marjolijn Mertz; Lorna W Role
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

Review 9.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 10.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.